MedTrace Logo

TIL Therapy for Patients With Advanced Solid Tumors

NCT06107894 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-10-30

No results posted yet for this study

Summary

This study is a phase I clinical trial to investigate the safety and tolerability of NEOG-100 in patients with advanced breast cancer and lung cancer. NEOG-100, an autologous tumor infiltrating lymphocytes (TILs), is infused intravenously into the patient after non-myeloablative (NMA) lymphodepletion treatment.

Conditions

Interventions

BIOLOGICAL

Tumor-infiltrating lymphocytes

After NMA Lymphodepletion, autologous TILs will be intravenous infused into patients.

DRUG

IL-2

IL-2 will be subcutaneous administrated for 14 days following TILs infusion.

Sponsors & Collaborators

  • NeogenTC

    lead INDUSTRY

Principal Investigators

  • Sung-Bae Kim, MD · Asan Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2025-09-30
Completion
2026-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06107894 on ClinicalTrials.gov